Individualized Case–Control Study of Accelerated Partial Breast Irradiation by Multicatheter Intertstitial Brachytherapy in Japanese Patients with Breast Cancer

Kazuhiko Sato, Y. Mizuno, H. Fuchikami, Masahiro Kato, T. Shimo, Jun Kubota, N. Takeda, Y. Inoue, H. Seto, T. Okawa
{"title":"Individualized Case–Control Study of Accelerated Partial Breast Irradiation by Multicatheter Intertstitial Brachytherapy in Japanese Patients with Breast Cancer","authors":"Kazuhiko Sato, Y. Mizuno, H. Fuchikami, Masahiro Kato, T. Shimo, Jun Kubota, N. Takeda, Y. Inoue, H. Seto, T. Okawa","doi":"10.5539/CCO.V2N1P127","DOIUrl":null,"url":null,"abstract":"Background: Breast-conserving surgery (BCS) followed by whole-breast irradiation (WBI) are the standard of care for treating early-stage breast cancer. The efficacy of accelerated partial breast irradiation (APBI) has recently been investigated as an alternative to WBI. Although we previously reported that multicatheter brachytherapy in APBI is feasible in Japanese patients, long-term data of several APBI techniques have not yet been obtained. Here we estimated the long-term efficacy of multicatheter brachytherapy in Japanese patients with breast cancer to validate its use an individualized case–control (ICC) analysis. Method: From October 2008 to March 2013, a total of 184 consequent patients with 188 tumors underwent BCS followed by multicatheter brachytherapy. A total of 120 consecutive patients (mean age, 55.1 years) with 122 tumors (pN0) who had at least 1 year of follow-up were enrolled in this analysis. Before lumpectomy, the insertion of applicators and delivery doses were simulated by computed tomography. After confirming the free margins and negative sentinel node metastases by frozen section analysis, the applicators were inserted. APBI therapy was initiated on the same day of surgery on the basis of the dose distribution analysis, at 32 Gy in 8 fractions over 5–6 days with a 2-cm tumor margin coverage. Regarding our prospective follow-up policy in this observational study, all patients had a predefined schedule including clinical examination every 3–4 months and mammography and breast magnetic resonance imaging (MRI) every 12 months. We performed ICC analysis to estimate the number of patients with ipsilateral breast tumor recurrence (IBTR). The 10-year risk of IBTR for each patient when undergoing with WBI was calculated using the web-based decision-making tool IBTR! and was adjusted during the real-time follow-up period using data obtained from an overview by the Early Breast Cancer Trialists’ Collaborative Group. Results: The median follow-up period was 3.1 years (range, 1.1–4.4 years). Most tumors (92.6%) were ?2 cm in diameter, and 89.4% were estrogen receptor-positive. Hormone therapy was administered in 86.7% and adjuvant chemotherapy in 20.0% patients. If all patients received WBI after BCS, we estimated IBTR in this group to be 1.1–2.8. Although 1 IBTR was observed, no tumor bed recurrence was recorded. Conclusions: Although this study involved only a small number of patients and short follow-up period, only 1 IBTR case was recorded, which was within the estimated range of local recurrence. Multicatheter brachytherapy using this technique may offer the same rates of local control as WBI in Japanese patients.","PeriodicalId":89904,"journal":{"name":"Cancer and clinical oncology","volume":"2 1","pages":"127"},"PeriodicalIF":0.0000,"publicationDate":"2013-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5539/CCO.V2N1P127","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer and clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5539/CCO.V2N1P127","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Background: Breast-conserving surgery (BCS) followed by whole-breast irradiation (WBI) are the standard of care for treating early-stage breast cancer. The efficacy of accelerated partial breast irradiation (APBI) has recently been investigated as an alternative to WBI. Although we previously reported that multicatheter brachytherapy in APBI is feasible in Japanese patients, long-term data of several APBI techniques have not yet been obtained. Here we estimated the long-term efficacy of multicatheter brachytherapy in Japanese patients with breast cancer to validate its use an individualized case–control (ICC) analysis. Method: From October 2008 to March 2013, a total of 184 consequent patients with 188 tumors underwent BCS followed by multicatheter brachytherapy. A total of 120 consecutive patients (mean age, 55.1 years) with 122 tumors (pN0) who had at least 1 year of follow-up were enrolled in this analysis. Before lumpectomy, the insertion of applicators and delivery doses were simulated by computed tomography. After confirming the free margins and negative sentinel node metastases by frozen section analysis, the applicators were inserted. APBI therapy was initiated on the same day of surgery on the basis of the dose distribution analysis, at 32 Gy in 8 fractions over 5–6 days with a 2-cm tumor margin coverage. Regarding our prospective follow-up policy in this observational study, all patients had a predefined schedule including clinical examination every 3–4 months and mammography and breast magnetic resonance imaging (MRI) every 12 months. We performed ICC analysis to estimate the number of patients with ipsilateral breast tumor recurrence (IBTR). The 10-year risk of IBTR for each patient when undergoing with WBI was calculated using the web-based decision-making tool IBTR! and was adjusted during the real-time follow-up period using data obtained from an overview by the Early Breast Cancer Trialists’ Collaborative Group. Results: The median follow-up period was 3.1 years (range, 1.1–4.4 years). Most tumors (92.6%) were ?2 cm in diameter, and 89.4% were estrogen receptor-positive. Hormone therapy was administered in 86.7% and adjuvant chemotherapy in 20.0% patients. If all patients received WBI after BCS, we estimated IBTR in this group to be 1.1–2.8. Although 1 IBTR was observed, no tumor bed recurrence was recorded. Conclusions: Although this study involved only a small number of patients and short follow-up period, only 1 IBTR case was recorded, which was within the estimated range of local recurrence. Multicatheter brachytherapy using this technique may offer the same rates of local control as WBI in Japanese patients.
日本乳腺癌患者多导管间质近距离加速部分乳房照射个体化病例对照研究
背景:保乳手术(BCS)加全乳照射(WBI)是治疗早期乳腺癌的标准治疗方法。加速部分乳房照射(APBI)作为WBI的替代方法,其疗效最近得到了研究。虽然我们之前报道了多导管近距离治疗APBI在日本患者中是可行的,但尚未获得几种APBI技术的长期数据。在这里,我们通过个体化病例对照(ICC)分析评估了日本乳腺癌患者多导管近距离放疗的长期疗效。方法:2008年10月至2013年3月,184例术后188例肿瘤行BCS +多导管近距离治疗。共有120例连续患者(平均年龄55.1岁),122例肿瘤(pno),随访至少1年,纳入本分析。在乳房肿瘤切除术前,通过计算机断层扫描模拟涂抹器的插入和给药剂量。通过冷冻切片分析确认游离缘和阴性前哨淋巴结转移后,插入涂抹器。根据剂量分布分析,在手术当天开始APBI治疗,剂量为32 Gy,分8次,5-6天,肿瘤边缘覆盖2 cm。关于本观察性研究的前瞻性随访政策,所有患者均有预先确定的时间表,包括每3-4个月进行一次临床检查,每12个月进行一次乳房x光检查和乳房磁共振成像(MRI)检查。我们采用ICC分析来估计同侧乳腺肿瘤复发(IBTR)患者的数量。使用基于网络的决策工具IBTR来计算每个患者在接受WBI时的10年IBTR风险!并在实时随访期间使用从早期乳腺癌试验者协作组的概述中获得的数据进行调整。结果:中位随访期为3.1年(范围1.1-4.4年)。绝大多数肿瘤(92.6%)直径为- 2cm, 89.4%为雌激素受体阳性。激素治疗占86.7%,辅助化疗占20.0%。如果所有患者在BCS后接受WBI,我们估计该组的IBTR为1.1-2.8。虽然观察到1个IBTR,但没有肿瘤床复发的记录。结论:虽然本研究患者数量少,随访时间短,但仅记录到1例IBTR病例,在局部复发的估计范围内。使用这种技术的多导管近距离治疗可以提供与日本WBI患者相同的局部控制率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书